Design Therapeutics Inc
DSGN
Get informed when a big investor buys or sells
+ FollowMarket Cap$936.23M
Close$
$0.27
98.3% downside
Current Fair Value
98.3% downsideOvervalued by 98.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $936.23 Million |
|---|---|
| Enterprise Value | $925.35 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.22 |
| Beta | 1.64 |
| Outstanding Shares | 62,505,340 |
Return
| Return on Equity | -35.07% |
|---|---|
| Return on Assets | -32.91% |
| Return on Invested Capital | -41.28% |
Valuation & Multiples
| P/E Ratio | -12.7 |
|---|---|
| PEG | -224.05 |
| Price to Sales | - |
| Price to Book Ratio | 5.23 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -10.99 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.34
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-0.38
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 1,553,900▲ Infinity% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 70.94%▲ 4.68% |
|---|---|
| Total Invested | $630.71M▲ 56.07% |
| Investors Holding | 141▲ 17.00% |
ESG Score
No data
About Design Therapeutics Inc
15 employeesDesign Therapeutics is a biotechnology company developing a new class of therapies based on a platform of gene targeted chimera (GeneTAC™) small molecules. The company’s lead program is focused on the treatment of Friedreich ataxia, foll...